Chronic Kidney Disease, Hypertension, Muscle Sympathetic Nerve Activity
Conditions
Keywords
Renin inhibitor, Patients, ACE inhibitor or ARB, Chronic Kidney Disease, Hypertension
Brief summary
The central hypothesis of this project is that Aliskiren causes a substantial decrease in MSNA in hypertensive patients with CKD.
Detailed description
Cardiovascular (CV) morbidity and mortality are frequently occurring problems in chronic kidney disease (CKD) patients. Apart from the so called traditional risk factors, also risk factors more or less specific to CKD contribute in the pathogenesis of these problems. There is strong evidence that the sympathetic hyperactivity, which often characterizes CKD, is one such factor. Previously, we have shown that angiotensin converting enzyme inhibitors (ACEi) and angiotensin II receptor blockers (ARB) reduce but not normalize this sympathetic hyperactivity. We re-analysed the cohort of patients who were investigated in the past and subsequently treated according to present guidelines. The results show that, despite of treatment, the unfavourable relation between sympathetic hyperactivity and clinical outcome still exits. This might mean that treatment is insufficient. In present study, we want to study the effect of Aliskiren 300mg on sympathetic nerve activity.
Interventions
DRUGAliskiren
Aliskiren 300mg per day for 6 weeks
Sponsors
UMC Utrecht
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
25 Years to 95 Years
Healthy volunteers
No
Inclusion criteria
* Patients with stable chronic kidney disease and hypertension: i.e. using antihypertensive drugs and/or blood pressure \> 145/90 mmHg when off medication. * Patients on ACE inhibitor or ARB
Exclusion criteria
* Patients with diabetes mellitus * Patients on renal replacement therapy * Pregnant patients Using of antihypertensive which cannot be stopped * Patients on immunosuppressive therapy and active nephrotic syndrome
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Normalisation of muscle sympathetic nerve activity | 1 year |
Secondary
| Measure | Time frame |
|---|---|
| Blood pressure and Blood tests | 1 year |
Countries
Netherlands
Contacts
Primary ContactLaima Siddiqi, MD
Outcome results
None listed